Roberta D'Arrigo
机构: Dirigente I Fascia, INMI L. Spallanzani Roma
每年引用次数
引用次数
引用: 1,860
H-指数: 27
I10-指数 : 39
出版物: 85
Peptidi antigenici per la vaccinazione anti-HIV-1
M Amicosante , V Colizzi , R D'Arrigo , A Sacchi
2004
Development of a post-exposure paediatric anti HIV-AIDS vaccine based on the combined synthetic/recombinant HIV peptides and BCG for boosting innate and acquired immunity. North-South transfer in Biotechnology of Tuberculosis and AIDS. University of Rome “Tor Vergata”. UNESCO Interdisciplinary Chair in Biotechnology. Vittorio Colizzi, Luc Montagnier, 2004.
Amicosante M , M Andreoni , A Anselmi , G Castelli
81 -92
2004
Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients
F Ceccherini-Silberstein , I Malet , L Fabeni , V Svicher
Antiviral Therapy 12 S6 -S6
26
2007
An improved helper-dependent adenoviral vector allows persistent gel-expression after im and overcames pre-existing immunity to adenovirus.
D Maione , Carlo DELLA ROCCA , P Giannetti , R D'Arrigo
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 98 5986 -5991
2001
Virological response and resistance in multi-experienced patients treated with raltegravir
F Ceccherini-Silberstein , D Armenia , R D'Arrigo , V Micheli
ANTIVIRAL THERAPY 13 ( 4) A20 -A20
20
2008
Baseline variability of HIV-1 integrase in multiexperienced patients treated with raltegravir: a refined analysis by pyrosequencing [abstract# 682]
F Ceccherini-Silberstein , D Armenia , R D'Arrigo , I Vandenbroucke
16th Conference on Retroviruses and Opportunistic Infections 8 -11
5
2009
Selection and coevolution of mutational patterns in the HIV-1 integrase characterized by pyrosequencing analysis
F Ceccherini-Silberstein , D Armenia , R D'Arrigo , I Vandenbroucke
Antiviral Therapy 14 ( 4) A125 -A125
2
2009
Does drug class multi-resistance affect survival? Analysis from a cohort of HIV patients who experienced treatment failure
M Zaccarelli , V Tozzi , P Lorenzini , F Forbici
ANTIVIRAL THERAPY 9 ( 4) U109 -U109
2
2004
Natural raltegravir-resistance is a rare event in integrase-inhibitors naïve patients, and when present, is confined to a restricted minority of secondary variants and is not associated with virological response to raltegravir
D Armenia , I Vandenbroucke , L Fabeni , R D'Arrigo
Infection 38 12 -12
1
2010
Clinical and genotypic correlates of K65R mutation in an unselected. cohort of HIV-infected persons naive for tenofovir
MP Trotta , S Bonfigli , FC Silberstein , D Zinzi
ANTIVIRAL THERAPY 9 ( 4) U115 -U116
1
2004
Characterization of gp41 evolution in a large cohort of HIV infected patients receiving T20 therapy as a single active drug
S Aquaro , V Svicher , R D'Arrigo , U Visco-Comandini
ANTIVIRAL RESEARCH 70 ( 1) A28 -A28
2006
The presence of selected mutations influence the disappearance of major protease resistance mutations during treatment interruption
F Ceccherini-Silberstein , M Santoro , C Gori , V Svicher
ANTIVIRAL THERAPY 10 ( 4) S171 -S171
2005
Mutations in HIV-1 reverse transcriptase associated with hypersusceptibility to non-nucleoside reverse transcriptase inhibitors: impact on virological response to efavirenz-based salvage therapy
V Tozzi , M Zaccarelli , F Ceccherini-Silberstein , P De Longis
ANTIVIRAL THERAPY 8 ( 3) U137 -U137
2003
METHOD OF ANTIGENIC PEPTIDE IDENTIFICATION AND RELATIVE USE FOR THE PREPARATION OF A VACCINE ANTI HIV-1
M Amicosante , G Cappelli , V Colizzi , R D'Arrigo
5
2005
APPLICATION OF GENOTYPIC TROPISM TESTING IN CLINICAL PRACTICE: VIROLOGICAL RESPONSE IN MULTI-EXPERIENCED HIV-POSITIVE PATIENTS TREATED WITH MARAVIROC-BASED THERAPY
S Nozza , V Svicher , F Canducci , C Alteri
INFECTION 39 S21 -S21
2011
SUCCESSFUL RESCUE THERAPY WITH MARAVIROC AND ETRAVIRINE (TMC-125) IN PATIENT WITH EARLY VIROLOGICAL FAILURE TO RALTEGRAVIR
C Tommasi , F Ceccherini-Silberstein , R D'Arrigo , R Bellagamba
INFECTION 37 90 -90
2009
Using a database of genotype resistance tests to describe characteristics related to detection of the multinucleoside resistance-associated Q151M mutation.
M Zaccarelli , F Forbici , F Soldani , S Bonfigli
HIV MEDICINE
2003
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14.
L Fabeni , C Alteri , D Di Carlo , N Orchi
Journal of Antimicrobial Chemotherapy 72 ( 10) 2837 -2845
13
2017
Cross-resistance among NNRTIs: evaluation of the option of recycling efavirenz after nevirapine failure
M Zaccarelli , A Cingolani , F Forbici , M Rizzo
Antiviral Therapy
2
2001
Factors predictive of multinucleoside analogue-resistance mutations in an unselected cohort of HAART-failed patients.
A Antinori , R D’Arrigo , G Liuzzi , M Bellocchi
AIDS
1
2000